2011

1. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: An open-label, randomised phase 2/3 trial

   The Lancet Infectious Diseases, Vol. 11, Núm. 4, pp. 273-283